Inoue Shigesato, Ogata Hiroaki, Dotake Yoichi, Takagi Koichi, Shiota Ayaka, Ishii Yumiko, Tanaka Kentaro, Kan-O Keiko, Inoue Hiromasa
Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Respiratory Medicine, National Hospital Organization Fukuokahigashi Medical Center, Koga, Fukuoka, Japan.
J Allergy Clin Immunol Glob. 2025 Mar 8;4(2):100448. doi: 10.1016/j.jacig.2025.100448. eCollection 2025 May.
Tezepelumab, a mAb targeting thymic stromal lymphopoietin (TSLP), reduces exacerbations in severe asthma. Four cases in which patients with severe asthma and chronic rhinosinusitis with nasal polyps showed improvements in both conditions after receiving tezepelumab treatment are presented.
tezepelumab是一种靶向胸腺基质淋巴细胞生成素（TSLP）的单克隆抗体，可减少重度哮喘的发作。本文介绍了4例重度哮喘合并慢性鼻-鼻窦炎伴鼻息肉患者在接受tezepelumab治疗后，两种疾病均得到改善的病例。
